• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a process for the preparation of thiotetrazoles comprising a step of converting N- (naphthalen-1-yl) -1,2,3,4-thiatriazol-5-amine to a thiolate anion in benzene in the presence of triethylamine, and a reaction step of this anion thiolate with an electrophilic bromide. These thiotetrazoles are usable as non-nucleoside reverse transcriptase inhibitors (ITINNs) for the treatment of HIV. In particular, 2 - ((1-naphthalen-1-yl) -1H-tetrazol-5-yl) thio) -N- (2-nitrophenyl) acetamide is a potent ITINN with nanomolar activity. The invention also relates to a process for preparing a thiotetrazole from a C1-N-alkyl substituted thiatriazole.
    公开号:CH710196B1
    申请号:CH00124/16
    申请日:2013-08-02
    公开日:2017-11-15
    发明作者:Yaroslav Rosocha Gregory；Alexander Batey Robert
    申请人:Yaroslav Rosocha Gregory；
    IPC主号:
    专利说明:

    Description: [0001] The present invention relates to a novel method for synthesizing thiotetrazoles useful as non-nucleoside reverse transcriptase inhibitors (ITINN). The pharmaceutically acceptable salts of ITINN thiotetrazoles can be used for the treatment of human immunodeficiency virus (HIV) infection and for the prevention of HIV, and also as a complement to other therapies and drugs used to treat HIV. Compounds that inhibit the function of HIV reverse transcriptase (HIV-RT) are known to inhibit the replication of HIV virus in infected cells. Therefore, compounds that inhibit HIV-RT may be useful in the treatment of HIV and used to prevent HIV infection. The thiotetrazole analogs prepared by the method appear to have nanomolar activity against HIV. In addition, thiotetrazoles and their pharmaceutically acceptable salts have been proposed as useful molecules for the development of medicaments useful for the treatment of inflammatory arthritis and hyperuricemia. Thiotetrazoles and their pharmaceutically acceptable salts can also be used as research tools for the development of new drugs and / or the enhancement of current drugs for the treatment of life-altering diseases such as HIV, inflammatory arthritis , and hyperuricemia.
    The method involves the use of thiatriazoles to produce a thiolate anion which is trapped in situ by an electrophile suitable to form a thiotetrazole compound. Thiatriazoles are useful molecules and are used as starting materials in this process because of their stability and safety associated with their use and storage. Thiatriazoles are converted to thiolate anion which can be combined with a suitable electrophile to form a molecule which may have therapeutic properties and / or which can be used as a research tool for the discovery of new drugs in the fields of infections. HIV and their prophylaxis and / or inflammatory arthritis and hyperuricemia.
    The process involves a solvent such as benzene, a substituted thiatriazole 1, a base, and an electrophile bromide which is trapped when the thiolate anion 2 is formed (Scheme 1).
    [0004] Scheme 1 gives an exemplary embodiment, wherein the pharmaceutical compound ITINN 3 is formed from 1. Intermediate 2 is trapped by the electrophilic bromide.
    [0005]
    In this example, thiotriazole 1 is heated in benzene at 50 ° C in the presence of triethylamine for 16 hours. The operation is followed by addition of the electrophilic bromide and stirring to form thiotetrazole 3.
    In another example, the thiatriazole is stirred in benzene at 60 ° C in the presence of triethylamine for at least 1 hour and the electrophilic is added and stirred for at least 1-24 hours at 60 ° C. The reaction is monitored by thin layer chromatography (TLC) or other analytical techniques. When the reaction is complete, the solvent is removed from the reaction mixture which is purified by crystallization and / or silica gel chromatography to give the product 2 - ((1- (naphthalen-1-yl) -1H-tetrazol-5 -yl) thio) -N- (2-nitrophenyl) acetamide in 45% yield, this product proving to be a potent ITINN with a nanomolar activity against wild type and mutated strains of HIV-1.
    The method can use different electrophiles bromides and different thiatriazoles to prepare different ITINN analogs useful as pharmaceutical preparations for treating HIV that causes acquired immunodeficiency syndrome (AIDS).
    In the present invention, the method has several advantages over other reported methods. For example, current methods for preparing thiotetrazole analogs use high temperature azides, which can be explosive, and isothiocyanates which are dangerous mutagens. This process is advantageous because it does not use these azides or nitriles.
    For example, 2 - ((1 - (naphthalen-1-yl) -1H-tetrazol-5-yl) thio) -N- (2-nitrophenyl) acetamide can be prepared, compound 3 (Scheme 1 ) by stirring in a batch reactor, adding 40.0 μΙ (0.262 mmol) of triethylamine to a stirred solution of 50.0 mg (0.219 mmol) of thiotriazole 1 in 2.19 ml of benzene, forming a light yellow mixture. The reaction mixture was then stirred for 18 hours, then 56.0 mg (0.219 mmol) of electrophile bromide was added and stirred for a further 12 hours. The progress of the reaction is monitored by layer chromatography
    权利要求:
    Claims (13)
    [1]
    After the completion of the reaction, the mixture is quenched with 20 ml of water, extracted with dichloromethane (3 × 25 ml) and the organic phase is dried over Na 2 SO 4, filtered and evaporated in vacuo. The crude residue was purified using column chromatography (ethyl acetate in hexanes) to give 25.0 mg (45%) of the pure product as a light yellow oil. IR (thin film, CHCl 3): 3322, 3066, 2924, 2355, 2325, 1701, 1604, 1585, 1498, 1434, 1396, 1341, 1275, 1242, 1149, 1088, 958, 913 cm -1. 1 H-NMR (400 MHz, CDCl3): 11.0 (1H, brs), 8.70 (1H, dd, J = 8.0, 1.0Hz), 8.41 (1H, m.p. dd, J = 8.0, 1.0 Hz), 8.15 (1H, m), 8.01 (1H, dd, J = 8.0, 1.0 Hz), 7.54-7.52 (5H, m), 7.47 (1H, d, J = 8.0Hz), 7.42 (1H, m), 4.28 (2H, s) ppm. 13 C NMR (400 MHz, CDCl 6): 165.6, 156.1, 155.4, 136.0, 134.5, 134.0, 132.2, 129.0, 128.8, 128.7, 127, 8, 126.0, 125.3, 124.4, 122.8, 128.8, 128.7, 122.0, 37.4 ppm. MS (IE) m / e (relative intensity): 407 (100), 243 (3), 230 (2), 213 (5), 211 (2), 186 (1), 169 (11), 139 (3) ), 113 (1) C19H15N5O3S. SMHD (IE) m / e C19H15N5O3S calculated mass = 407.0926, found = 407.0920. For example, N- (naphthalen-1-yl) -1,2,3,4-thiatriazol-5-amine 1 is prepared using the general method for the synthesis of thiatriazole and the crude residue is purified by chromatography on silica gel (10-30% ethyl acetate in hexanes) to give 1.20 g (75%) pure thiatriazole 1 as a light ocher solid (mp = 122 ° C). IR (thin film, CHCl3): 3391, 3046, 2986, 1550, 1499, 1470, 1424, 1351, 1263, 1220, 1155, 1118, 1050, 894, 741, 703 cm -1. 1 H NMR (400 MHz, CDCl 3): 11.2 (1H, brs), 8.12 (1H, m), 8.04 (1H, dd, J = 7.5, 1.0Hz), 7.99. (1H, m), 7.84 (1H, d, J = 7.5Hz), 7.64-7.56 (3H, m) ppm. RMI 13 (400 MHz, DMSO-d6): 177.5, 136.6, 134.6, 129.1, 127.3, 127.3, 127.0, 126.6, 126.6, 122, 4, 119.1 ppm. MS (IE) m / e (relative intensity): 228 (4), 187 (6), 185 (100), 169 (12), 158 (17), 153 (26), 141 (22), 127 (86) ), 92 (6), 75 (5), 62 (2). SMHD (IE) m / e CnH8N4S calculated mass = 228.0470, found = 228.0475. The thiolate anion 2 is prepared using the following procedure. To prepare 1- (naphthalen-1-yl) -1H-tetrazole-5-thiol 2, 39.0 μΙ (0.285 mmol) of triethylamine are added to a stirred solution at 50 ° C of 50.0 mg ( 0.219 mmol) of naphthyltriazole 1 in 2.19 ml of benzene. The reaction mixture is stirred at 50 ° C for 22 hours and quenched with 25.0 ml of water and 50.0 ml of ethyl acetate, washed with 3 x 20 ml of 1M HCl, 3 x 20 ml of water and 3 x 20 ml of brine. The organic phase was dried over sodium sulfate and evaporated in vacuo to give 70.0 mg (100% yield) of 2 (mp = 120-122 ° C) as light pink crystals. IR (thin film, CHCl 3): 3046, 2986, 1499, 1470, 1424, 1351, 1263, 1220, 1155, 1118, 1050, 894, 741, 703 cm -1. 1 H NMR (400 MHz, DMSO-d 6): 8.21 (1H, d, J = 8.0 Hz), 8.01 (1H, d, J = 8.0 Hz), 7.79. 7.55 (4H, m), 7.39 (1H, d, J = 8.5Hz) ppm. RMI / T13C (400 MHz, DMSO-d6): 134.6, 132.0. 129.6.129.0.128.8.128.3, 127.4,126.4,125.3,122.2 ppm (missing 1 carbon). MS (ESI +) m / e (relative intensity): 229 (90), 228 (4), 227 (2), 217 (3), 213 (2), 212 (14), 204 (3), 201 (100) ), 200 (5), 197 (4), 187 (4), 186 (6), 185 (2) SMHD (ESI) m / e CnH9H4S calculated mass = 229.05479, found = 229.05525. 2-Bromo-N- (2-nitrophenyl) acetamide 4 is prepared by adding 242.0 μΙ (2.77 mmol) of bromoacetyl bromide dropwise to a stirred solution of 462.0 g (2%). 52 mmol) of nitroaniline in 25 ml of chloroform, forming a yellow precipitate. The reaction mixture is stirred at room temperature for 12 hours, then quenched with 75 ml of water and extracted with dichloromethane (3 x 50 ml). Organic washes were dried with sodium sulfate, filtered and evaporated in vacuo to give 391.0 mg (51%) of a light brown solid. In the case where there has not been complete consumption of the aniline, the crude material is again reacted with bromoacetyl bromide allowing complete conversion of the nitroaniline to the amide product. In this case, purification is not necessary because of the high purity obtained and the quantitative yield relative to nitroaniline. 1 H NMR (400 MHz, toluene): 11.2 (1H, brs), 8.74 (1H, d, J = 8.0Hz), 8.26 (1H, d, J = 8.0 Hz), 7.71 (1H, t, J = 8.0 Hz), 7.27 (1H, t, J = 8.0 Hz) ppm. 13 C NMR (400 MHz, CDCl 3): 165.1, 136.1, 134.0, 126.1, 124.4, 122.2, 29.6 ppm. ITINN 3 appears to have nanomolar activity against wild-type strains of HIV. The process can be electrophiles bromides, R-Br, where R denotes the following groups: R = o-nitrophenylacetamide, m-nitrophenylacetamide, p-nitrophenylacetamide o-methylphenylacetamide m-methylphenylacetamide p-methylphenylacetamide o-chlorophenylacetamide m-chlorophenylacetamide p-chlorophenylacetamide claims
    1. Chemical process for the preparation of a thiotetrazole of formula:

    Comprising a step of converting N- (naphthalen-1-yl) -1,2,3,4-thiatriazol-5-amine to a thiolate anion of formula 2 in benzene in the presence of triethylamine

    2 and a reaction step of this thiolate anion 2 with an electrophilic bromide of formula R-BR, wherein R is selected from the group consisting of: o-nitrophenylacetamide, m-nitrophenylacetamide, p-nitrophenylacetamide, o-methylphenylacetamide, m-methylphenylacetamide, p-methylphenylacetamide, o-chlorophenylacetamide, m-chlorophenylacetamide, and p-chlorophenylacetamide.
    [2]
    2. Chemical process according to claim 1, wherein the thiolate anion is obtained by heating at 50 ° C in benzene for 22 hours and then isolated.
    [3]
    3. Chemical process according to claim 1, wherein the anionic anion 2 is obtained by stirring in benzene for 18 hours, and trapped by the electrophilic bromide in situ.
    [4]
    The chemical process according to claim 1, wherein the thiolate anion 2 is obtained by stirring in benzene at 60 ° C for at least 1 hour, and trapped by the electrophilic bromide in situ.
    [5]
    5. Chemical process according to claim 1, characterized in that it is non-continuous and used in a batch-operated vessel.
    [6]
    6. Chemical process according to claim 5, wherein the vessel contains an inert atmosphere.
    [7]
    The chemical process of claim 6, wherein the inert atmosphere is a noble gas.
    [8]
    8. Chemical process according to claim 1, characterized in that it is continuous and carried out in a reaction vessel comprising grooves and / or prefabricated channels having dimensions in the range of 0.100 micrometers to 200 micrometers.
    [9]
    The chemical process according to claim 8, wherein said reaction vessel is capable of reaching temperatures in the range of -150 ° C to 400 ° C.
    [10]
    10. Chemical process according to one of claims 1 to 9, wherein the electrophilic bromide is 2-bromo-N- (2-nitrophenyl) acetamide 4 and wherein the thiotetrazole formed is 2 - ((1 - (naphthalene). 1-yl) -1H-tetrazol-5-yl) thio) -N- (2-nitrophenyl) acetamide 3.
    [11]
    11. A chemical process for preparing a thiotetrazole from an N-C 1-4 alkyl substituted thiatriazole in the presence of benzene and an amine in a reaction vessel, comprising the steps of: a) mixing the solvent and thiatriazole in the tank, b) adding the amine to the reaction vessel and mixing for a period of time, c) adding the electrophile bromide to the vessel, d) heating the reaction vessel to a temperature in the range. ranging from 50 ° C to 150 ° C for a period of time greater than 12 hours.
    [12]
    The chemical process of claim 11, wherein the amine is triethylamine.
    [13]
    13. Chemical process according to claim 11, wherein the reaction vessel is selected from a batch reactor and a continuous reactor.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP2017088632A|2017-05-25|Compounds useful in the synthesis of benzamide compounds
    JP6781030B2|2020-11-04|L-carnosine derivative or salt thereof, and method for producing L-carnosine or salt thereof
    JP2021526531A|2021-10-07|How to make Refite Glast
    EP2661422B9|2016-09-07|Method and intermediate products for the preparation of agomelatine
    CH710196B1|2017-11-15|A method for preparing non-nucleoside reverse transcriptase inhibitor thiotetrazoles | for the treatment of HIV.
    JP2021514371A|2021-06-10|Method for Producing Prostaglandin Analogs That Donate Nitric Oxide
    CN111170885A|2020-05-19|Preparation of levomilnacipran hydrochloride
    WO2019036441A1|2019-02-21|Processes for the preparation of niraparib and intermediates thereof
    EP3609877B1|2020-12-23|Process for the synthesis of firocoxib
    JP5137576B2|2013-02-06|Method for sulfonation of 1,2-benzisoxazole-3-acetic acid
    JP6887022B2|2021-06-16|Methods for Producing Ketolide Compounds
    JP4913589B2|2012-04-11|One-pot production method of 1,2-benzisoxazole-3-methanesulfonamide
    JP6797839B2|2020-12-09|New manufacturing method of teriflunomide
    JP6660393B2|2020-03-11|Method for preparing 4-cyanopiperidine hydrochloride
    WO2018051042A1|2018-03-22|Novel method for the synthesis of agomelatine
    JP2015526507A|2015-09-10|Method for purifying fluvoxamine free base and method for producing high purity fluvoxamine maleate using the same
    EP2938595B1|2017-06-14|Method for the synthesis of a hydrazine that can be used in the treatment of the papilloma virus
    JPH061776A|1994-01-11|Production of substituted pyrazinecarbonitrile
    FR2790472A1|2000-09-08|CYCLOBUTENE-3, 4-DIONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
    US8133993B1|2012-03-13|Hydrogenolytic denitration of polynitro compounds: pentanitrohexaazaisowurtzitane
    JP2021504418A|2021-02-15|Method for producing 2- | -4,5-dihydro-1H-imidazole and its hydrogen sulfate
    FR2670208A1|1992-06-12|DERIVATIVES OF PHENYL-1 DIHYDRO 1-4-ARYLALCOYLAMINO-3-OXO-4-PYRIDAZINES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS.
    FR2615853A1|1988-12-02|NOVEL PROCESS FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE PIPERAZINE DERIVATIVES, DERIVATIVES AND NOVEL INTERMEDIATES OBTAINED
    EP1776341A1|2007-04-25|Method for preparing n-aminopiperedine and its salts
    JPH1045739A|1998-02-17|Production of monosubstituted nitroguanidine compound
    同族专利:
    公开号 | 公开日
    CA2912334A1|2015-02-05|
    WO2015015240A1|2015-02-05|
    US10017479B2|2018-07-10|
    CA2912334C|2020-08-04|
    US20160130238A1|2016-05-12|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US7642277B2|2002-12-04|2010-01-05|Boehringer Ingelheim International Gmbh|Non-nucleoside reverse transcriptase inhibitors|
    US7517998B2|2004-06-01|2009-04-14|Boehringer Ingelheim International Gmbh|Non nucleoside reverse transcriptase inhibitors|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    PCT/IB2013/001733|WO2015015240A1|2013-08-02|2013-08-02|New process to make non-nucleosidal reverse transcriptase inhibitorsfor the treatment of hiv|
    [返回顶部]